A physician prepares a measles vaccine. Photo: Daniel Mihailescu/AFP via Getty Images

A changing picture has emerged of the U.S.' susceptibility to epidemics of infectious diseases over the next decade — driven by organized anti-vaccine activity and the lack of incentives to develop new or more effective vaccines, along with inadequate mosquito control measures.

The big picture: Reducing the risk of new epidemics will require expanding the use of existing vaccines, especially for measles and seasonal influenza, as well as introducing new vaccines for any vector-borne or zoonotic diseases that emerge.

The main infectious disease epidemics to look out for:

  1. Measles: More than 40,000 measles cases occurred in Europe in the first half of 2018. With regular travel between North America and Europe, it's possible that on any given week measles cases are being imported into the U.S. Several western states with strong anti-vaccine movements —including Washington, Oregon, Idaho and Texas — are highly vulnerable to outbreaks because of low vaccine coverage, in some cases well below the 90%–95% immunization rates needed to achieve adequate herd immunity for measles.
  2. Seasonal influenza: Influenza is one of the most fatal infectious diseases in the U.S., especially among the very old and very young. Most of the 180 American children who perished in the 2018 flu epidemic were not vaccinated, despite strong recommendations from public health officials. (An anti-vaccine lobby may have promoted misleading information about both flu and the flu vaccine.) Flu is now being reported in the Southern Hemisphere this summer and will return to North America this winter. Given that influenza kills up to 50,000 Americans every winter, flu vaccinations, especially for children, are paramount.
  3. Vector-borne diseases: Diseases from infected ticks (e.g., Lyme disease), mosquitoes (e.g., West Nile, dengue and Zika), and fleas (e.g., typhus) have tripled over the past 13 years. Nine new disease pathogens spread by mosquitoes or ticks have also been either newly discovered or introduced into the U.S. over this period. A yellow fever epidemic in Brazil could emerge in U.S. Gulf Coast states where the Aedes aegypti mosquito — the most efficient mosquito vector — is found. There is probably a need for vaccines to prevent Lyme Disease, West Nile virus and Chagas disease — among others — but they are not being developed because of perceived market inadequacy. Also, as the recent HPV vaccine has shown, it’s increasingly difficult to introduce new vaccines in the U.S.

Peter Hotez is a professor of pediatrics and molecular virology and microbiology at Baylor College of Medicine, where he is also Dean of the National School of Tropical Medicine.

Go deeper

Ford names James Farley as new CEO amid ongoing turnaround effort

James Hackett, left, is retiring as Ford CEO. Jim Farley, right, takes over Oct. 1. Photo: Ford

Ford announced Tuesday that James Farley will take over as its next CEO, replacing James Hackett, 65, who is retiring after three years in the job.

Why it matters: It leaves Farley to complete the company's ongoing turnaround effort. The transition will be that much harder as the industry tries to navigate the coronavirus-induced economic slowdown which shuttered Ford plants for two months on the eve of some of its most important vehicle launches.

Updated 2 hours ago - Politics & Policy

Watch the full "Axios on HBO" interview with President Trump

In this episode of “Axios on HBO”, President Trump discusses his handling of the coronavirus pandemic, the upcoming election and much more with National Political Correspondent Jonathan Swan.

The interview was filmed on Tuesday, July 28 and aired Monday, Aug. 3 on HBO.

Mergers and acquisitions make a comeback

Illustration: Sarah Grillo/Axios

A slew of high-profile headlines led by Microsoft's expected acquisition of social media video app TikTok helped bring the Nasdaq to another record high on Monday.

Why it matters: The mergers-and-acquisitions market looks like it's bouncing back, joining the revived credit and equity markets as well as the market for new public companies through IPOs and special purpose acquisition companies (SPACs).